The Ligase Chain Reaction (LCR) is a DNA amplification technique that can either be utilized in conjunction with Polymerase Chain reaction (PCR), or as an alternative to PCR, due to its equal ability to support exponential signal amplification. LCR is being used as a tool in molecular biology and diagnostic applications, especially for nucleotide sequence detection and single nucleotide polymorphism (SNP) detection. However, performance problems and non-specificity issues, including the accumulation of false-positive signals, often make conventional LCR an unlikely choice in clinical diagnostics and in the development of ligation-based applications. Herein, we propose a novel Hot Start approach for LCR. Similar to the benefit seen for Hot Start activation methods in PCR, the Hot Start LCR approach is predicted to have substantially improved specificity and performance, compared to conventional LCR. Hot Start LCR employs chemically modified ligation components, including oligonucleotide probes and cofactors, containing thermally labile protecting groups for heat-triggered LCR. We believe that this approach will be a significant improvement to current methods because it has the high potential to replace a number of applications where traditional PCR, Gap-LCR or PCR/ligation combination approaches are either expensive, not applicable, or show problematic performance.

Public Health Relevance

As of 2009, the molecular diagnostics market has an average annual growth rate of 12- 15%, with an estimated value of $3-3.5 billion worldwide, where $2 to $2.5 billion of the market is in the USA. The Ligase Chain Reaction (LCR) is a substantial component of this market. We propose to improve the specificity of conventional LCR by developing a novel approach that includes Hot Start activation of LCR by using modified oligonucleotide probes and cofactors with thermolabile protecting groups.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43GM093562-01A1
Application #
8059150
Study Section
Special Emphasis Panel (ZRG1-IMST-J (15))
Program Officer
Maas, Stefan
Project Start
2011-01-15
Project End
2012-01-14
Budget Start
2011-01-15
Budget End
2012-01-14
Support Year
1
Fiscal Year
2011
Total Cost
$99,462
Indirect Cost
Name
Trilink Biotechnologies, Inc.
Department
Type
DUNS #
945720043
City
San Diego
State
CA
Country
United States
Zip Code
92121